What Is TB-500?

TB-500 is a research peptide sold under a market name associated with thymosin beta-4, a naturally occurring protein. Exactly which molecule a given vial contains varies by source — some references treat "TB-500" as full-length thymosin beta-4, others as a fragment corresponding to its active region — so the definitive identity check is the mass-spectrometry value on the batch-specific Certificate of Analysis. It is used in preclinical research and is not an approved drug.

The short answer

TB-500 is a lab-synthesized research peptide associated with thymosin beta-4 (often written Tβ4), a protein found across many tissue types. Researchers study it for a region of the parent protein's activity, though sources differ on whether "TB-500" denotes the full-length protein or a shorter piece of its active region — the exact identity of a given vial is confirmed by the mass-spectrometry value on its Certificate of Analysis. Like other research peptides, it is typically supplied as a lyophilized powder and verified by analytical testing before use. It is not FDA-approved and is not a medicine.

Composition and specifications

Note: the exact identity of a given TB-500 vial is confirmed by its mass-spectrometry value on the Certificate of Analysis for that batch, since the TB-500 name is used loosely across the market for thymosin beta-4-related material.

TB-500 vs. thymosin beta-4

This distinction trips people up, so it's worth being precise. Thymosin beta-4 is the full, naturally occurring 43-amino-acid protein. TB-500 is a name used in the research-chemical market, and usage of it varies: some references treat "TB-500" as full-length thymosin beta-4, while others describe it as a shorter synthetic peptide corresponding to an active region of that sequence. In practice the two names are used loosely, and sometimes interchangeably, across vendors. Rather than assert one definition, the accurate approach is to defer to the analytical data — the identity of any given vial is settled by its mass-spectrometry value: full-length thymosin beta-4 lands near ~4.9 kDa, whereas a short active-region fragment would be far lighter. That is why the definitive check on which molecule is in a given vial is the mass-spec value reported on its batch-specific Certificate of Analysis — not the label.

What has research examined?

As with most research peptides, the bulk of the TB-500 literature is preclinical — animal and cell-based work rather than controlled human trials. Because TB-500 is discussed in close connection with thymosin beta-4, much of the relevant literature is indexed under the parent protein, and the identity question above is worth keeping in mind when reading it. Investigated areas in the thymosin beta-4 / TB-500 literature include:

• Cell-migration and tissue-repair models
• Actin-binding and cytoskeletal signaling (a known role of thymosin beta-4)
• Angiogenesis-related pathways
• Inflammation models

The best-characterized activity in this research area is actin binding. Thymosin beta-4 is described in the laboratory literature as a G-actin-sequestering peptide — it binds monomeric (globular) actin and thereby influences how actin filaments assemble, a process that underlies cell shape, motility, and directed migration. Studies that examine TB-500-labelled material generally situate it against this same actin-related biology. This is a description of molecular behavior observed in experimental systems, not a claim that administering the peptide produces any effect in a person.

Building on that, a large share of the preclinical work uses cell-migration and tissue-repair models: scratch and wound-closure assays in cell culture, and animal models tracking markers of repair in tissues such as skin, cornea, or cardiac muscle. A related body of papers examines angiogenesis-associated pathways — signaling connected with the formation of new blood vessels — and inflammation models, where various markers are measured under defined experimental conditions. In each case the endpoints are laboratory measurements in non-human systems.

The parent protein is often described in the literature as a “moonlighting” molecule — one sequence associated with several distinct activities beyond actin binding. That breadth is part of why the thymosin beta-4 / TB-500 literature spans so many model systems, from cell-culture assays to studies in whole animals. It also means results are scattered across sub-fields and are not easily summarized into a single effect, and because much of the work is indexed under thymosin beta-4, isolating findings that pertain specifically to a TB-500-labelled material can itself be difficult.

As with other peptides in this class, part of the literature is methodological rather than biological — reports on stability, reconstitution, and handling that treat the material as a research reagent. And as with the wider peptide field, preclinical signals frequently do not carry over to controlled human studies: the distance between an observation in a cell or animal model and a demonstrated clinical outcome is substantial, and for TB-500 that distance has not been bridged by rigorous trials. Reviews therefore tend to frame this body of work as descriptive and preliminary.

These describe research directions in non-human models, not established human effects. Human clinical evidence for TB-500 specifically is limited, and the interpretive caution is compounded by the identity ambiguity discussed above: because "TB-500" and "thymosin beta-4" are used loosely across sources, a given study or product may not refer to the same molecule. The mass-spectrometry value on a batch-specific Certificate of Analysis is what ties any particular sample to the literature. Nothing in this research base establishes a benefit, dose, or safety profile for human use.

How is it characterized and tested?

Research-grade TB-500 is verified the same way as other peptides: identity confirmed by mass spectrometry, purity measured by HPLC, and both reported on a Certificate of Analysis. An independent COA lets a researcher confirm they have the intended molecule at a known purity before beginning work. See peptide handling and storage for how samples are kept stable once received.

Common questions

Is TB-500 the same as TB4 / thymosin beta-4?

Usage varies. "TB-500" is a market name associated with thymosin beta-4: some references treat it as the full-length protein, others as a fragment corresponding to its active region. Because the name is used loosely, the mass-spectrometry value on a batch-specific Certificate of Analysis is what confirms which molecule a given vial contains.

Is TB-500 approved for human use?

No. It is not FDA-approved and is studied in research settings only.

Is it often studied alongside other peptides?

In the literature it's sometimes discussed alongside BPC-157, as both appear in tissue-repair research models — though they are distinct compounds with different origins.